Anti-Human CD38 (HB-7) – Purified No Carrier Protein
Anti-Human CD38 (HB-7) – Purified No Carrier Protein
Product No.: C994
- -
- -
Clone HB-7 Target CD38 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names HB7, T10, ADP-ribosyl cyclase Isotype Mouse IgG1 κ Applications FA , FC , IF , WB |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Immunogen BJAB Human B-cell Line Product Concentration ≥1.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥90% monomer by analytical SEC and SDS-Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. State of Matter Liquid Storage and Handling This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Additional Applications Reported In Literature ? WB IF FA FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity HB-7 activity is directed against human CD38. Background CD38 is a type II transmembrane glycoprotein that functions as an adhesion molecule with ectoenzymatic activities that contribute to intracellular calcium mobilization 1,2. Dysregulation is associated with a number of diseases, including HIV, autoimmune, type II diabetes mellitus, osteoporosis, and hematological malignancies such as multiple myeloma (MM) 1, a neoplasm characterized by clonal expansion of malignant plasma cells 2.
Because CD38 is strongly and uniformly expressed on myeloma cells, but has limited expression on normal cells, anti-CD38 antibody HB-7 was used to develop an antibody drug conjugate (ADC) capable of killing human myeloma and lymphoma cell lines 3. This ADC is composed of HB-7 conjugated to a chemically modified ricin molecule and is able to block protein synthesis in multiple myeloma cells and in normal bone marrow mononuclear cells. HB-7 was developed by immunizing BALB/c mice with viable cells of the Human Burkitt lymphoma B cell line BJAB 4. The antibody binds to an epitope in the carboxyl terminus of CD38 between residues 273-285, which is also the site of enzyme activity 5. Binding is unaffected by the presence of NAD+ and does not influence CD38 catalytic activity 6. Antigen Distribution CD38 is expressed on plasma cells, other lymphoid and myeloid cell populations, natural killer cells, B cells, activated T cells, some peripheral regulatory T cells, monocytes, lymph node germinal center lymphoblasts, intrafollicular cells, dendritic cells, erythrocytes, platelets, committed stem cells, Purkinje cells, neurofibrillary tangles in the brain, epithelial cells in the prostate, β‐cells in the pancreas, retinal cells in the eye, and sarcolemma of smooth and striated muscle. CD38 can also be detected on early osteoclast progenitors but not on osteoblasts and mature osteoclasts. CD38 expression is very high and uniform on all malignant cells in multiple myeloma. While generally found on the plasma membrane, CD38 has also been detected in the cytosol or nucleus in brain, pancreatic acinar cells, smooth muscle, and osteoclasts. Ligand/Receptor CD31, Hyaluronic acid NCBI Gene Bank ID UniProt.org Research Area Cell Adhesion . Cell Biology . Immunology References & Citations1. van de Donk NW, Janmaat ML, Mutis T, et al. Immunol Rev. 270(1):95-112. 2016. 2. Morandi F, Horenstein AL, Costa F, et al. Front Immunol. 9:2722. 2018. 3. Goldmacher VS, Bourret LA, Levine BA, et al. Blood. 84(9):3017-3025. 1994. 4. Tedder TF, Clement LT, Cooper MD. Tissue Antigens24(3):140-149. 1984. 5. Hoshino S, Kukimoto I, Kontani K, et al. J Immunol.;158(2):741-747. 1997. 6. Berthelier V, Laboureau J, Boulla G, et al. Eur J Biochem. 267(10):3056-3064. 2000. 7. Collins A, Rothman N, Liu K, et al. JCI Insight. 2(5):e90063. 2017. 8. Caeser R, Di Re M, Krupka JA, et al. Nat Commun. 10(1):4543. 2019. 9. Imura Y, Ando M, Kondo T, et al. JCI Insight. 5(14):e136185. 2020. 10. Caeser R, Gao J, Di Re M, et al. Nat Protoc. 16(5):2499-2519. 2021. 11. Shukla S, Ying W, Gray F, et al. Nat Chem Biol. 17(7):784-793. 2021. 12. Nachmias B, Khan DH, Voisin V, et al. Leukemia. 36(5):1283-1295. 2022. 13. Volodarsky I, Shimoni S, Haberman D, J Cardiovasc Dev Dis. 10(1):2. 2022. Technical ProtocolsCertificate of Analysis |
Related Products
- -
- -
Formats Available
- -
- -
Prod No. | Description |
---|---|
C994 | |
C1001 | |
C998 | |
C999 | |
C1002 | |
C1003 | |
C1004 | |
C1005 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.